Compare Stocks: RARE, ERAS, PTCT, and GRFS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$14.77 -3.7%	$17.80	$1.75 ▼ $24.28	$5.17B	0.64	4.23 million shs	8.69 million shs
GRFS Grifols	$7.31 -1.2%	$7.75	$6.96 ▼ $10.23	$4.98B	0.67	370,705 shs	367,746 shs
PTCT PTC Therapeutics	$65.37 -3.9%	$72.27	$57.74 ▼ $90.87	$5.46B	0.55	824,472 shs	3.86 million shs
RARE Ultragenyx Pharmaceutical	$14.51 +0.1%	$23.88	$12.73 ▼ $39.89	$1.43B	0.31	5.41 million shs	13.33 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	0.00%	-6.99%	-13.52%	+8.05%	+784.43%
GRFS Grifols	0.00%	-3.18%	-8.51%	-1.22%	-25.03%
PTCT PTC Therapeutics	0.00%	-1.04%	-7.30%	-17.23%	+7.78%
RARE Ultragenyx Pharmaceutical	0.00%	+1.47%	-42.69%	-47.12%	-49.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$14.77 -3.7%	$17.80	$1.75 ▼ $24.28	$5.17B	0.64	4.23 million shs	8.69 million shs
GRFS Grifols	$7.31 -1.2%	$7.75	$6.96 ▼ $10.23	$4.98B	0.67	370,705 shs	367,746 shs
PTCT PTC Therapeutics	$65.37 -3.9%	$72.27	$57.74 ▼ $90.87	$5.46B	0.55	824,472 shs	3.86 million shs
RARE Ultragenyx Pharmaceutical	$14.51 +0.1%	$23.88	$12.73 ▼ $39.89	$1.43B	0.31	5.41 million shs	13.33 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	0.00%	-6.99%	-13.52%	+8.05%	+784.43%
GRFS Grifols	0.00%	-3.18%	-8.51%	-1.22%	-25.03%
PTCT PTC Therapeutics	0.00%	-1.04%	-7.30%	-17.23%	+7.78%
RARE Ultragenyx Pharmaceutical	0.00%	+1.47%	-42.69%	-47.12%	-49.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	2.64	Moderate Buy	$22.09	49.57% Upside
GRFS Grifols	1.67	Reduce	$10.00	36.80% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$98.50	50.68% Upside
RARE Ultragenyx Pharmaceutical	2.48	Hold	$34.42	137.22% Upside

Current Analyst Ratings Breakdown

Latest RARE, ERAS, PTCT, and GRFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $39.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$33.00 ➝ $39.00
9/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/14/2026	PTCT PTC Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform	$98.00
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/4/2026	RARE Ultragenyx Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$28.00 ➝ $19.00
9/4/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$43.00 ➝ $32.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
9/3/2026	RARE Ultragenyx Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$77.00 ➝ $28.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
GRFS Grifols	$8.51B	0.58	$1.42 per share	5.16	$12.64 per share	0.58
PTCT PTC Therapeutics	$1.73B	3.15	$8.77 per share	7.45	($2.56) per share	-25.54
RARE Ultragenyx Pharmaceutical	$673M	2.13	N/A	N/A	($0.83) per share	-17.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	38.47	5.46	0.27	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	30.69	2.02	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)

Latest RARE, ERAS, PTCT, and GRFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.08	1.09%	N/A	42.11%	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Latest RARE, ERAS, PTCT, and GRFS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	8.29	8.29
GRFS Grifols	1.10	2.37	0.81
PTCT PTC Therapeutics	N/A	3.39	3.28
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
GRFS Grifols	N/A
PTCT PTC Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.20%
GRFS Grifols	0.19%
PTCT PTC Therapeutics	5.30%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

RARE, ERAS, PTCT, and GRFS Headlines

Recent News About These Companies

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Strong Trading Volume Following Analyst Upgrade

1 hour ago | americanbankingnews.com

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

3 hours ago | theglobeandmail.com

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity

3 hours ago | theglobeandmail.com

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

3 hours ago | finance.yahoo.com

Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVI™ to Treat ...

September 18 at 8:13 PM | newswise.comN

Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo

September 18 at 8:13 PM | medcitynews.comM

Ultragenyx sets $3.95m list price for fatal rare disease therapy

September 18 at 3:12 PM | emjreviews.comE

Ultragenyx Pharmaceutical stock jumps on Fayuvi FDA approval and fresh Cantor Fitzgerald target

September 18 at 3:12 PM | ad-hoc-news.deA

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says

September 18 at 12:35 PM | marketbeat.com

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

September 18 at 11:50 AM | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgrade

September 18 at 10:39 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00

September 18 at 10:35 AM | marketbeat.com

Ultragenyx Wins FDA Approval For FAYUVI In Pediatric MPS IIIA

September 18 at 10:11 AM | rttnews.com

Ultragenyx wins first-ever FDA approval in Sanfilippo syndrome type A

September 18 at 10:11 AM | thepharmaletter.comT

Canaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $39.00

September 18 at 8:41 AM | marketbeat.com

Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

September 18 at 8:30 AM | zacks.com

Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

September 18 at 8:05 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

September 18 at 3:00 AM | seekingalpha.com

Ultragenyx Shares Rise After FDA Approval for Sanfilippo Syndrome Treatment

September 17 at 11:42 PM | finance.yahoo.com

Ultragenyx Pharmaceutical Rises After FDA Approves Fayuvi for Sanfilippo Syndrome Type A

September 17 at 11:42 PM | marketwatch.com

RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy

September 17 at 11:42 PM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RARE, ERAS, PTCT, and GRFS Company Descriptions

Erasca NASDAQ:ERAS

$14.77 -0.57 (-3.72%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.84 +0.07 (+0.44%)

As of 09/18/2026 07:30 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Grifols NASDAQ:GRFS

$7.31 -0.09 (-1.22%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.30 -0.01 (-0.21%)

As of 09/18/2026 04:43 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

PTC Therapeutics NASDAQ:PTCT

$65.37 -2.63 (-3.87%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$65.36 -0.01 (-0.02%)

As of 09/18/2026 07:46 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.51 +0.01 (+0.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.55 +0.04 (+0.25%)

As of 09/18/2026 07:59 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, ERAS, PTCT, and GRFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, ERAS, PTCT, and GRFS Earnings

Compare Dividends

Latest RARE, ERAS, PTCT, and GRFS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, ERAS, PTCT, and GRFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, ERAS, PTCT, and GRFS Company Descriptions

Erasca NASDAQ:ERAS

Grifols NASDAQ:GRFS

PTC Therapeutics NASDAQ:PTCT

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools